Barr Pharmaceuticals upgraded to "outperform"

08/06/04 - Wachovia Securities

NEW YORK, August 6 (New Ratings) - Analysts at Wachovia Securities upgrade Barr Pharmaceuticals (BRL) from "market perform" to "outperform," while raising their estimates for the company.

In a research note published this morning, the analysts mention that Barr Pharmaceuticals is poised for robust growth in the long term, since the company is transitioning from a pure play generic to a balanced proprietary/generic hybrid. The company indicated that it intends to be financially prudent during the transition process, according to Wachovia Securities. The EPS estimate for FY2005 has been raised from $2.30 to $2.37.